Find a Clinical Trial
Clinical trials offer patients access to emerging treatments that are shaping the future of cancer care. Our clinical research program works alongside your care team to evaluate new therapies, improve how treatments are delivered and enhance quality of life during and after treatment.
If you are interested in participating in a clinical trial, ask your physician if you qualify. To make our clinical trials available to all CARTI patients, all of our physicians serve as sub-investigators; this means that your treating physician can enroll you onto a clinical trial if you are eligible.
Participation in research is always voluntary. For further information on clinical trials, please visit http://www.clinicaltrials.gov.
If you have any additional questions for or about CARTI’s Research Team, please call 501.906.4199 or email Research@CARTI.com.
Principal Investigator: Dr. Kamal Patel, M.D.
MT GROUP
Sponsor: The MT Group
Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients
DISEASE SITE:
STAGE:
TRIAL DESIGN: Cooperative Group
TRIAL TYPE: Biospecimen
ENROLLMENT STATUS: Actively Enrolling
Principal Investigator: Dr. Ryan Hall, M.D.
CARIS
- CARIS Fusion
- CARIS 901
- CARIS Matched 701
DISEASE SITE:
STAGE:
TRIAL DESIGN: Right on Time
TRIAL TYPE: Biospecimen
ENROLLMENT STATUS: Not Enrolling
Principal Investigator: Dr. Ryan Hall, M.D.
RIVER-MPDAC; C3651021
Sponsor: Pfizer, Inc.
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
DISEASE SITE: Colorectal Cancer, Pancreatic Cancer
STAGE: Phase II, Phase III
TRIAL DESIGN: Industry
TRIAL TYPE: Investigational Product
ENROLLMENT STATUS: Actively Enrolling
ClinicalTrials.gov ID: NCT06989437
Principal Investigator: Dr. Sam Makhoul, M.D., FASCO
NRG-CC012CD; SYMON
Sponsor: NRG Oncology [Mercy Research]
Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment
DISEASE SITE: Solid Tumor
STAGE: Phase III
TRIAL DESIGN: Investigator Initiated
TRIAL TYPE: Interventional
ENROLLMENT STATUS: Actively Enrolling
ClinicalTrials.gov ID: NCT06279013
Principal Investigator: Dr. Andrew Briggler, M.D.
PAN-TUMOR MRD STUDY; FH-PRWS-07-002
Sponsor: Flatiron Health, Inc.
Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers
DISEASE SITE: Esophageal Cancer, Melanoma, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer, Solid Tumor
STAGE:
TRIAL DESIGN: Biospecimen
TRIAL TYPE: Biospecimen
ENROLLMENT STATUS: Actively Enrolling
ClinicalTrials.gov ID: NCT06605404
Principal Investigator: Dr. David Hays, M.D., FACR
CYBRID-02 (BSK22-2562)
Sponsor: Elephas Bioscience Corporation
Observational basket trial to collect tissue to train and validate a live tumor diagnostic platform.
DISEASE SITE: Solid Tumor
STAGE:
TRIAL DESIGN: Biospecimen
TRIAL TYPE: Observational
ENROLLMENT STATUS: Actively Enrolling
ClinicalTrials.gov ID: NCT05520099
Principal Investigator: Dr. David Kuperman, M.D.
TROPION-SWISH; D926UL0001
Sponsor: AstraZeneca Pharmaceutical LP
An open-label, single-arm study of prophylaxis of Datopotamab deruxtecan (Dato-DXd) -related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
DISEASE SITE: Breast Cancer, Non-Small Cell Lung Cancer (NSCLC)
STAGE: Phase IV
TRIAL DESIGN: Industry
TRIAL TYPE: Interventional, Investigational Product
ENROLLMENT STATUS: Actively Enrolling
ClinicalTrials.gov ID: NCT07357597
Principal Investigator: Dr. Ryan Hall, M.D.
MERK MK2870-023
Sponsor: Merck & Co.
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
DISEASE SITE: Non-Small Cell Lung Cancer (NSCLC)
STAGE: Phase III
TRIAL DESIGN: Industry
TRIAL TYPE: Interventional, Investigational Product
ENROLLMENT STATUS: Actively Enrolling
Clinicaltrials.gov Number: NCT06422143
Principal Investigator: Dr. Sam Makhoul, M.D., FASCO
ADJUVANT WIDER; CLEE011012011
Sponsor: Novartis AG
A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy In a Close-to Clinical Practice Patient Population With HR+ HER2− Early Breast Cancer
DISEASE SITE: Breast Cancer
STAGE: Phase III
TRIAL DESIGN: Industry
TRIAL TYPE: Interventional, Investigational Product
ENROLLMENT STATUS: Actively Enrolling
Clinicaltrials.gov Number: NCT05827081
Principal Investigator: Dr. David Kuperman, M.D.
FOURLIGHT-03; C4391024
Sponsor: Pfizer, Inc.
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer who Have not Received any Prior Systemic Anticancer Treatment for Advanced/Metastatic Disease
DISEASE SITE: Breast Cancer
STAGE: Phase III
TRIAL DESIGN: Industry
TRIAL TYPE: Interventional, Investigational Product
ENROLLMENT STATUS: Actively Enrolling
Clinicaltrials.gov Number: NCT06760637